Trials / Completed
CompletedNCT00094848
Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
A Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Efficacy, and Exposure to TRM-1 (Fully Human Monoclonal Antibody to the TRAIL-R1) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Human Genome Sciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, efficacy and exposure to TRM-1 in subjects with relapsed or refractory Non-Hodgkin's Lymphoma (NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRAIL-R1 mAb (TRM-1; HGS-ETR1) |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-12-01
- Completion
- 2007-05-01
- First posted
- 2004-10-27
- Last updated
- 2013-08-02
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00094848. Inclusion in this directory is not an endorsement.